Pulished Date October, 2018
ID: 7869
Share on
Share on

Asia Pacific Cancer Metabolism Based Therapeutics Market By Therapy (Biological Drug Therapies, Targeted Drug Therapies), By Drug Type (Enasidenib, CPI-613, Others), By Indication (Melanoma, Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML), Metastatic Renal Cell Carcinoma, Others), By Region - Asia Pacific Industry Analysis, Size, Share, Growth, Trends, And Forecasts (2018-2023)

Pulished: October, 2018
ID: 7869
Pages: 145

Asia Pacific Cancer Metabolism Based Therapeutics market size was approximately USD XX million in 2018 and showing a huge increase with a CAGR of XX% and is anticipated to reach USD XX million by 2023.  

The hike in this market is driven by several factors some of them include an increase in the number of people who are diagnosed with cancer every year, smoking tobacco, exposing the body to different types of radiations, heredity, chemicals. Introducing new ways of treating cancers also increasing the market share. The high cost of treatment may drag back the market value in some of the developing countries. Around 3% of the cancer cases and 7% of cancer-related deaths in the U.S. are attributed to pancreatic cancer.

The market is segmented by Therapy, Drug type, and Indication. By therapy, the market is categorized into Biological drug therapies and Targeted drug therapies. By drug type, the market is further divided into CPI-613, Enasidenib, others. CPI-613 was introduced recently in 2018 which is considered as the best drug to treat pancreatic cancer. Enasidenib also got its importance in treating pancreatic cancer. According to a report from American Cancer Society in 2018, 53 thousand people were diagnosed with pancreatic cancer and around 43 thousand of them are experiencing a threat to their lives. By Indication, the market is segregated into Melanoma, Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML), Metastatic Renal Cell Carcinoma, and others. Around twenty one thousand cases of Acute Myeloid Leukemia attacks were reported by American Cancer Society in 2018, out of which 50% are experiencing the terminal stage. Many non-profit organizations came into the picture to help people and increased awareness about symptoms and treatment process of pancreatic cancer which is helping the market to increase its size.

By geography, the market is segmented into India, China, Japan, South Korea, and others. As there are increasing cases of cancer every year in developing countries like India and China, the potential for market expansion is expected to be high in these countries.

Some of the prime manufacturers of Cancer Metabolism Based Therapeutics are AstraZeneca, Novartis, Celgene, Rafael Pharmaceuticals, Cornerstone Pharmaceuticals, Polaris Group, Agios Pharmaceuticals, Taiho Pharmaceuticals, 3-V biosciences, Calithera Biosciences, and BERG Health.

1. Introduction                                 

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods                          

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                               

                2.2 Research Phases                      

                                2.2.1 Secondary Research           

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling      

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                       

                3.1 Executive Summary                

                3.2 Key Inferences                         

                3.3 Epidemology                              

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                    

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market                              

5. Market Segmentation                                              

                5.1 Therapy                       

                                5.1.1 Introduction           

                                5.1.2 Biological Drug Therapies  

                                5.1.3 Targeted Drug Therapies  

                                5.1.4  Y-o-Y Growth Analysis, By Therapy              

                                5.1.5  Market Attractiveness Analysis, By Therapy            

                                5.1.6  Market Share Analysis, By Therapy             

                5.2 Drug Type                   

                                5.2.1 Introduction           

                                5.2.2 Enasidenib              

                                5.2.3 CPI-613     

                                5.2.4 Other Drugs            

                                5.2.5 Y-o-Y Growth Analysis, By Drug Type           

                                5.2.6 Market Attractiveness Analysis, By Drug Type         

                                5.2.7 Market Share Analysis, By Drug Type          

                5.3 Indication                    

                                5.3.1 Introduction           

                                5.3.2 Melanoma              

                                5.3.3 Myelodyspalstic Syndrome (MDS)

                                5.3.4 Acute Myeloid Leukemia (AML)    

                                5.3.5 Metastatic Renal Cell Carcinoma    

                                5.3.6 Others      

                                5.3.7 Y-o-Y Growth Analysis, By Indication           

                                5.3.8 Market Attractiveness Analysis, By Indication         

                                5.3.9 Market Share Analysis, By Indication           

6. Geographical Analysis                                              

                6.1 Introduction                               

                                6.1.1 Regional Trends    

                                6.1.2 Impact Analysis     

                                6.1.3 Y-o-Y Growth Analysis        

                                                6.1.3.1 By Geographical Area

                                                6.1.3.2 By Therapy

                                                6.1.3.3 By Drug Type

                                                6.1.3.4 By Indication

                                6.1.4  Market Attractiveness Analysis     

                                                6.1.4.1 By Geographical Area

                                                6.1.4.2 By Therapy

                                                6.1.4.3 By Drug Type

                                                6.1.4.4 By Indication

                                6.1.5  Market Share Analysis      

                                                6.1.5.1 By Geographical Area

                                                6.1.5.2 By Therapy

                                                6.1.5.3 By Drug Type

                                                6.1.5.4 By Indication

                6.2 China                             

                6.3 India                              

                6.4 Japan                            

                6.5 South Korea                               

                6.6 Australia                      

7. Strategic Analysis                                       

                7.1 PESTLE analysis                         

                                7.1.1 Political     

                                7.1.2 Economic 

                                7.1.3 Social         

                                7.1.4 Technological         

                                7.1.5 Legal          

                                7.1.6 Environmental       

                7.2 Porter’s Five analysis                              

                                7.2.1 Bargaining Power of Suppliers        

                                7.2.2 Bargaining Power of Consumers    

                                7.2.3 Threat of New Entrants     

                                7.2.4 Threat of Substitute Products and Services              

                                7.2.5 Competitive Rivalry within the Industry     

8. Market Leaders' Analysis                                        

                8.1 AstraZeneca                               

                                8.1.1 Overview 

                                8.1.2 Product Analysis   

                                8.1.3 Financial analysis  

                                8.1.4 Recent Developments       

                                8.1.5 SWOT analysis       

                                8.1.6 Analyst View          

                8.2 Novartis                       

                8.3 Celgene                       

                8.4 Rafael Pharmaceuticals                         

                8.5 Cornerstone Pharmaceuticals                            

                8.6 Polaris Group                             

                8.7 Agios Pharmaceuticals                           

                8.8 Taiho Pharmaceuticals                           

                8.9 3-V Biosciences                         

                8.10 Calithera Biosciences                           

                8.11 BERG Health                            

9. Competitive Landscape                                           

                9.1 Market share analysis                            

                9.2 Merger and Acquisition Analysis                       

                9.3 Agreements, collaborations and Joint Ventures                         

                9.4 New Product Launches                         

10. Market Outlook and Investment Opportunities                                         

Appendix                                           

                a) List of Tables                

                b) List of Figures                              

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of Therapy, by  Drug type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market

                                                                                                                          

  1. Asia Pacific Diabetes Care Devices Market By Application, From 2018-2023 ( USD Million )
  2. Asia Pacific Blood Glucose Monitoring Market By Region, From 2018-2023 ( USD Million )
  3. Asia Pacific Insulin Delivery Market By Region, From 2018-2023 ( USD Million )
  4. Japan Diabetes Care Devices Market By Application, From 2018-2023 ( USD Million )
  5. China Diabetes Care Devices Market By Application, From 2018-2023 ( USD Million )
  6. India Diabetes Care Devices Market By Application, From 2018-2023 ( USD Million )
  7. Australia Diabetes Care Devices Market By Application, From 2018-2023 ( USD Million )
  8. South Korea Diabetes Care Devices Market By Application, From 2018-2023 ( USD Million )

Please wait. . . . Your request is being processed

LICENCE TYPE

$ 1234 3335

Clients
clients
clients
clients
clients
clients
clients
Request Sample